UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011506
Receipt number R000013462
Scientific Title A randomized phase II study of degarelix combined with anti-androgen for prostate cancer
Date of disclosure of the study information 2013/08/17
Last modified on 2015/05/13 16:53:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized phase II study of degarelix combined with anti-androgen for prostate cancer

Acronym

Degarelix with anti-androgen for prostate cancer

Scientific Title

A randomized phase II study of degarelix combined with anti-androgen for prostate cancer

Scientific Title:Acronym

Degarelix with anti-androgen for prostate cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To determine the benefit of degarelix/bicalutamide versus degarelix monotherapy in patients with prostate cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in serum level of prostate specific antigen at Day 28.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Degarelix

Interventions/Control_2

Degarelix + bicalutamide

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Histologically proven prostate adenocarcinoma.
Patients indicated for androgen deprivation therapy.

Key exclusion criteria

Previous or present endocrine therapy for prostate cancer.

Target sample size

90


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hirotsugu Uemura

Organization

Kinki University Faculry of Medicine

Division name

Urology

Zip code


Address

377-2, Ohno-higashi, Osaka-sayama

TEL

0723660221

Email

huemura@med.kindai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masahiro Nozawa

Organization

Kinki University Faculry of Medicine

Division name

Urology

Zip code


Address

377-2, Ohno-higashi, Osaka-sayama

TEL

0723660221

Homepage URL


Email

nozawa06@med.kindai.ac.jp


Sponsor or person

Institute

South-Kinki Prostate Cancer Study Group

Institute

Department

Personal name



Funding Source

Organization

Astellas Pharma Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 08 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 05 Month 01 Day

Last follow-up date

2015 Year 05 Month 13 Day

Date of closure to data entry

2015 Year 05 Month 13 Day

Date trial data considered complete

2015 Year 05 Month 13 Day

Date analysis concluded

2015 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 08 Month 17 Day

Last modified on

2015 Year 05 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013462


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name